Targeted Therapy and Venclexta Combinations for AML and a Look Ahead to ASH ’21

Naval Daver, MD, and Robert Figlin, MD, discuss FLT3, TP53, and venetoclax combinations in the management of AML patients and what to look forward to at ASH 2021.